Antonio Giordano/X
Aug 23, 2025, 14:54
Antonio Giordano: FourLight-3 Trial for Atirmociclib in HR+/HER2- Metastatic Breast Cancer
Antonio Giordano, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by DAVA Oncology on X, adding:
“FourLight-3, a phase 3 study to look at the selective CDK4i Atirmociclib + AI vs treatment physician choice CDK4/6i (ribo, palbo, abema) in 1st line HR+/HER2- a/mBC.”
Quoting DAVA Oncology‘s post:
“Can selective CDK4 inhibition improve outcomes in HR+/HER2– BC?
Atirmociclib showed manageable safety in Phase 1/2A. The Phase 3 FourLight-3 trial now tests it head-to-head vs CDK4/6i in 1L.”
More posts featuring Antonio Giordano on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 23, 2025, 14:52
Aug 23, 2025, 14:36
Aug 23, 2025, 14:11
Aug 23, 2025, 13:51
Aug 23, 2025, 13:38
Aug 23, 2025, 13:32
Aug 23, 2025, 13:11
Aug 23, 2025, 13:00